Bioresearch PharmaS.A.

Manufacture of basic pharmaceutical products

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2024-03-14
Share capital
274 777,20 PLN
Activity description

Bioresearch Pharma is a company that repurposes existing topical drugs for dermatological applications, focusing on conditions such as androgenetic alopecia and psoriasis. They offer BRP-011, a therapy aimed at promoting hair growth, and BRP-007, a new treatment for plaque psoriasis with a unique mechanism of action. The company develops advanced medicines by utilizing well-tested therapeutic substances for new indications and creating novel drug formulations.

Registered address
ul. Zygmunta Glogera 2/11, 02-051 Warszawa, Poland
Website
bioresearchpharma.comWebsite active
Email
Email address current
Phone
Social media

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 76.29kMedianUSD 110.97kAverageUSD 2.03m
Net profit
This companyUSD -1.54mMedianUSD -121.74AverageUSD 63.64k
Operating costs
This companyUSD 1.61mMedianUSD 167.82kAverageUSD 1.89m
Assets
This companyUSD 2.97mMedianUSD 118.27kAverageUSD 1.41m

Bank accounts

Registered as a VAT taxpayer on 2022-03-09. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication dateEvent
Mar 22, 2024Transformation

Public aid

PurposeGross amount
Aid for SMEs for innovation support
$1.5M

Tenders

No recorded participation in tenders.

Authorized Representatives

Łukasz Jarosław Zybaczyński – President of the Management Board
Katarzyna Koziak – Attorney-in-fact (joint)
Robert Litka – Management Board Member

Manner of representation

In the case of a one-person management board, the sole member of the management board is entitled to independently represent the company. In the case of a multi-member management board, representation of the company requires the joint action of two members of the management board or one member of the management board jointly with a commercial proxy.

Supervisory board

Paweł Augustyn – Supervisory Board Member
Bartosz Krzesiak – Supervisory Board Member
Mariusz Gujski – Supervisory Board Member
Jan Kospin – Supervisory Board Member
Maciej Tadeusz Wieloch – Supervisory Board Member

Beneficial owners

Person

Competitors

Name
Pexon Polandsp. z o.o.
Xenira Pharmaceuticalssp. z o.o.
Sanford Biotechsp. z o.o.

Change history

DateEvent
2024-10-18Share capital change
2024-05-07Share capital change
2024-03-14Entered in the register

FAQ

Last updated: 2026-10-03